01/07/2021 | Press release | Distributed by Public on 01/07/2021 06:48
Fresenius Medical Care, the world's leading provider of products and services for people with chronic kidney failure, will offer the Seraph 100 Microbind Affinity Blood Filter from ExThera Medical Corporation in several European countries as of now. Both companies have signed a co-marketing and distribution agreement, effective in January 2021 and covering Belgium, Denmark, France, Germany, Italy, Luxembourg, the Netherlands, Norway, Sweden and the United Kingdom.
ExThera Medical's Seraph 100 adsorber is used in critical care for the extracorporeal removal of pathogens from the bloodstream and can be operated with Fresenius Medical Care acute dialysis machines. Similar to the dialysis process, the blood is purified by pumping it through the filter. The Seraph 100 has been CE-certified since 2019 for the reduction of pathogens during bloodstream infections, in addition to therapy with anti-infectives.
'With the innovative adsorber technology from ExThera Medical, we are strengthening our offering in the field of critical care solutions, which is one of the key areas of the company's strategy 2025,' said Dr Katarzyna Mazur-Hofsäß, Fresenius Medical Care's CEO for Europe, Middle East and Africa. 'Bloodstream infections often lead to kidney, lung or multiorgan failure. A treatment with the Seraph 100 can eliminate more than 90 percent of the pathogens in the patient's blood for every pass through the filter. And the first treatment results of its use with COVID-19 patients are very promising.'
'We are very excited to partner with Fresenius Medical Care to broaden European availability of the Seraph 100,' said Bob Ward, Founder and CEO of ExThera Medical. 'This distribution agreement ensures as many patients as possible will have access to a therapy that can help critically ill patients suffering from pathogen-oriented bloodstream infection.'
Fresenius Medical Care Ventures, the venture capital unit of Fresenius Medical Care, has a financial stake in ExThera Medical since 2016.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.